Finance

Lists
Why is CLLS up 2.14%?
Dive Deeper
CLLS:NASDAQ
Cellectis SA
$1.43
+2.14%
(+0.030) 1D
$1.43
0.00% (0.00)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLLS...
Open
$1.45
High
$1.47
Low
$1.42
Mkt. cap
106.78M
Avg. vol.
144.02K
Volume
47.51K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
Open
$1.45
High
$1.47
Low
$1.42
Mkt. cap
106.78M
Avg. vol.
144.02K
Volume
47.51K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
3.00
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA
CEOAndré Choulika
Employees227
Founded1999
Headquarters-
SectorBiotechnology
Websitecellectis.com
Analyst ratings
Based on 4 analysts giving stock ratings to CLLS in the past 3 months
Hold
Buy
1
Hold
2
Sell
1
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CLLS in the last 3 months.
Highest
Current $1.43
$8.00 (+459.44%)
Average
$4.10 (+186.71%)
Lowest
$1.30 (-9.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lukas Shumway
Barclays
Sell
Downgraded
$1.30
-9.1%
09/15/2026
Jack Allen
Robert W. Baird
Buy
Maintained
$8.00
+459.4%
09/15/2026
Nick Abbott
Wells Fargo
Hold
Reiterated
$3.00
+109.8%
09/15/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
09/15/2026
Gena Wang
Barclays
Buy
Initiated
$9.00
+529.4%
05/28/2026
William Maughan
Clear Street
Buy
Maintained
$9.00
+529.4%
03/20/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$4.00
+179.7%
01/13/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
11/11/2025
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
37.16M
12.21M
7.55M
6.90M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.07M
24.44M
27.19M
24.98M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.21M
4.80M
5.59M
5.74M
Operating expense
29.12M
29.56M
32.72M
30.42M
Total operating expenses
29.12M
29.56M
32.72M
30.42M
Operating income
8.04M
-17.35M
-25.17M
-23.52M
Other non operating income
-7.06M
-8.80M
5.90M
2.28M
EBT including unusual items
589.00K
-26.74M
-17.72M
-21.79M
EBT excluding unusual items
589.00K
-26.74M
-17.72M
-21.79M
Income tax expense
-
-423.00K
46.00K
25.00K
Effective tax rate
-
1.58%
-0.26%
-0.11%
Other operating expenses
-154.00K
320.00K
-63.00K
-290.00K
Net income
589.00K
-26.32M
-17.76M
-21.82M
Net profit margin
1.58%
-215.60%
-235.36%
-316.03%
Earnings per share
0.02
-0.24
-
-
Interest and investment income
2.31M
2.08M
1.84M
1.55M
Interest expense
-2.11M
-2.03M
-1.93M
-2.01M
Net interest expenses
206.00K
44.00K
-83.00K
-468.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
11.16M
-15.33M
-22.13M
-20.39M
Gain or loss from assets sale
-
-
-5.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps